Status:
COMPLETED
Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy
Lead Sponsor:
Mustafa Kemal University
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Hypertension
Left Ventricular Hypertrophy
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The study hypothesis: Valsartan as an angiotensin II receptor blocker treatment has beneficial effects on both midwall mechanics and myocardial functions in hypertensive patients with Left ventricular...
Eligibility Criteria
Inclusion
- hypertension with left ventricular hypertrophy
Exclusion
- clinical or laboratory evidence of secondary hypertension
- heart failure
- ischemic heart disease
- valvular heart disease
- arrhythmias
- peripheral vascular disease
- chronic obstructive pulmonary disease
- neurologic disorders
- diabetes mellitus
- renal dysfunction
- notable systemic disease
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT01425411
Start Date
November 1 2006
End Date
November 1 2008
Last Update
August 30 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mustafa Kemal University School of Medicine, Department of Cardiology
Antioch, Antioch, Turkey (Türkiye), 31100